DocWire News Editors

DocwireNews

Risankizumab is a humanized monoclonal interleukin-23 antagonist antibody used for the treatment of plaque psoriasis, generalized pustular psoriasis (GPP). and erythrodermic psoriasis (EP). In a recent paper published in Clinical Pharmacokinetics, the study researchers assessed relationships between risankizumab exposures and crucial efficacy and safety variables in a cohort of patients with moderate-to-severe plaque psoriasis, GPP, or EP after being treated with 75 or 150 mg subcutaneous doses at weeks zero and four and every 12 weeks subsequently.The study authors correlated risankizumab average plasma concentrations with probabilities of achieving the primary efficacy endpoints, which were Psoriasis Area and Severity Index (PASI) 75, PASI 90, PASI 100, and Static Physicians Global Assessment (sPGA) 0/1. Data were evaluated on Japanese (n = 225) and non-Japanese (n = 1,678) moderate-to-severe plaque psoriasis patients participating in global trials or a Japan Phase 2/3 trial.In the Japanese patient cohort, the exposure-efficacy relationships were comparable with those of patients in global Phase 3 trials. The researchers reported a 16-week efficacy plateau for 150 mg subcutaneous dose; the PASI 90 response probability was 77%, while the sPGA 0/1 response probability was 88%. Exposures were not as great in heavier patients for the 75 mg dose for PASI 100 response and other efficacy responses. No correlation between risankizumab average plasma concentrations and key safety variables (any adverse event, serious adverse event, infection and infestation, and serious infection during treatment) were observed in exposure-safety analyses&mdash;this was similar to results from global trials.The study authors concluded that risankizumab 150 mg was efficient in treating Japanese psoriasis patients and posed no significant safety concerns.

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Jordana Jampel

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Latest News

Efficacy and Safety of Risankizumab to Treat Psoriasis

Psoriasis

Risankizumab is a humanized monoclonal interleukin-23 antagonist antibody used for the treatment of plaque psoriasis, generalized pustular psoriasis.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe